Endpoints
death, tumor
DISEASE PROGRESSION, SECONDARY, TUMOR
The primary endpoints were the safety and tolerability of avelumab after LITT and the objective response rate to treatment. The secondary endpoints included OS, defined as the time from enrollment to death from any cause, and PFS, defined as the time from enrollment to documented disease progression. Other secondary endpoints included the detection of protein biomarkers in serum samples, changes in circulating immune cells, and pathologic and immunologic analyses of the tumor specimens.